GCIG Clinical Trials By Lead Cooperative Group

Trialsort descending Trial Number Trial Description Contact Person Additional Info Lead Cooperative Group
55994

NCT00039338

Randomized phase III study of neoadjuvant chemotherapy followed by surgery vs. concomitant radiotherapy and chemotherapy in FIGO Ib2, IIa > 4 cm or IIb cervical cancer EORTC-GCG
AGO – OVAR OP.3 (LION)

ClinicalTrials.gov Identifier: NCT00712218

Lymphadenectomy In Ovarian Neoplasms AGO-OVAR
AGO-OVAR 2.21

NCT01837251

A prospective randomized Phase III trial of carboplatin/gemcitabine/bevacizumab vs. carbolatin/pegylated liposomal doxorubin/bevacizumab in patients with platinum-sensitive recurrent ovarian cancer AGO-OVAR
ALIENOR-GINECO-OV222

ClinicalTrials.gov Identifier: NCT01770301

Efficacy and Safety of Bevacizumab (Avastin) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours GINECO
ANZGOG 0902 / GOG 0274 OUTBACK TRIAL - A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone
AURELIA (GCIG/Roche)

ClinicalTrials.gov Identifier: NCT00976911

A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer GINECO
CHORUS

ClinicalTrials.gov Identifier: NCT00075712

A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma NCRI
DESKTOP III (AGO-OVAR OP.4)

ClinicalTrials.gov Identifier: NCT01166737

A randomized trial evaluating cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer AGO-OVAR
DGCG/ EORTC 55102

ClinicalTrials.gov Identifier: NCT01244789

A Phase III Trial of Postoperative Chemotherapy or no Further Treatment for Patients With Node-negative Stage I-II Intermediate or High Risk Endometrial Cancer NSGO
EWOC-1

ClinicalTrials.gov Identifier: NCT02001272

Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer GINECO
FANDANGO

ClinicalTrials.gov Identifier: NTC02730416

ENGOT-EN1/FANDANGO: A Randomized Phase II Trial of First-line Combination Chemotherapy With Nintedanib / Placebo for Patients With Advanced or Recurrent Endometrial Cancer NSGO
G-GOC-1002

ClinicalTrials.gov Identifier: NCT01048853

Conservative surgery for women with low-risk, early stage cervical cancer G-GOC
G-GOC-lOOl

ClinicalTrials.gov Identifier: NCT00614211

A Phase III Randomized Clinical Trial of Laparoscopic or Robotic Radical Hysterectomy Versus Abdominal Radical Hysterectomy in Patients With Early Stage Cervical Cancer The goal of this clinical research study is to compare the long-term outcomes of different surgical methods for the treatment of cervical cancer. The long-term outcome of a total abdominal radical hysterectomy (TARH) will be compared against laparoscopy. In this study, the laparoscopy will be done with or without robotic technology. G-GOC
GCIG/JGOG3017 Randomized Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary JGOG
GOG 0213

ClinicalTrials.gov Identifier: NCT00565851

Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer GOG
GOG 240

ClinicalTrials.gov Identifier: NCT00803062

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer GOG
GOG 263/KGOG-0801

ClinicalTrials.gov Identifier: NCT01101451

Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery GOG
GOG0252

ClinicalTrials.gov Identifier: NCT00951496

Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer GOG
GOG0262

ClinicalTrials.gov Identifier: NCT01167712

Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer GOG
GOG0274

ClinicalTrials.gov Identifier: NCT01414608

A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The Outback Trial (ANZGOG 0902 /GOG 0274 / RTOG 1174) Contact: Kathleen Moore GOG
GOG233/ACRIN6671

ClinicalTrials.gov Identifier: NCT00416455

Fludeoxyglucose F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer ACRIN
ICON 6 A randomised trial of concurrent cediranib [AZD2171] (with platinum-based chemotherapy) and maintenance cediranib in women with platinum-sensitive relapsed ovarian cancer. NCRI
ICON 8 An international phase III randomised trial of dose-fractionated chemotherapy compared to standard three-weekly chemotherapy, following immediate primary surgery or as part of delayed primary surgery, for women with newly diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer NCRI
ICON7 A randomised, two arm, multi-centre Gynaecologic Cancer InterGroup phase III trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in first line treatment of patients with epithelial ovarian cancer. NCRI
INTERLACE

ClinicalTrials.gov Identifier: NCT01566240

A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with locally advanced cervical cancer. NCRI
iPocc Trial

ClinicalTrials.gov Identifier: NCT01506856

IntraPeritoneal therapy for Ovarian Cancer with Carboplatin (GOTIC-001 / JGOG3019) GOTIC
KGOG 2015

ClinicalTrials.gov Identifier: NCT01527396

Prospective, Observational Study of Low-risk Criteria for Nod Metastasis in Endometrial Cancer KGOG
mEOC

ISRCTN83438782

A GCIG Intergroup multicentre trial of open label carboplatin and paclitaxel +/- bevacizumab compared with oxaliplatin and capecitabine +/- bevacizumab as first line chemotherapy in patients with mucinous Epithelial Ovarian Cancer. NCRI
MITO CERV 2

ClinicalTrials.gov Identifier: NCT00997009

MITO
MITO12

ClinicalTrials.gov Identifier: NCT01061619

Pathway to diagnosis of ovarian cancer: an observational retrospective multicentred study MITO
MITO7

ClinicalTrials.gov Identifier: NCT00660842

First line weekly carboplatin and paclitaxel versus every 3 weeks carboplatin/paclitaxel in patients with ovarian cancer: phase III multicentre trial MITO
MITO8

ClinicalTrials.gov Identifier: NCT00657878

Liposomal doxorubicin stealth vs. carboplatin/paclitaxel in recurrent ovarian cancer patients with platinum-free interval between 6-12 months MITO
NCIC CTG CX.5/GCIG SHAPE

ClinicalTrials.gov Identifier: NCT01658930

A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer;
NCIC CTG OV.21

ClinicalTrials.gov Identifier: NCT00993655

A phase II/III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus IV carboplatin plus paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy
NiCCC

ISRCTN No: ISRCTN50772895

A Randomised Phase II Study Of Nintedanib (BIBF1120) Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium SGCTG
NSGO/AVANOVA

ClinicalTrials.gov Identifier: NTC02354131

Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. NSGO
NSGO/PALEO

ClinicalTrials.gov Identifier: NTC02730429

A randomized phase II trial of Palbociclib in combination with Letrozole versus Letrozole Monotherapy for patients with Estrogen Receptor Positive advanced or recurrent Endometrial cancer. NSGO
OVAR12 (BI 1199.15)

ClinicalTrials.gov Identifier: NCT01015118

Multicenter, randomised, double-blind phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and paclitaxel in patients with advanced ovarian cancer AGO-OVAR
OVAR16 (VEG110655)

ClinicalTrials.gov Identifier: NCT00866697 

A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy versus Placebo in Women who have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer AGO-OVAR
PORTEC-3 Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma DGOG
RTOG-0724

ClinicalTrials.gov Identifier: NCT00980954

Phase III Randomized Study of Concurrent Chemotherapy and Pelvic RT with or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy RTOG
SOLO-2 (ENGOT-GCIG/AstraZeneca)

ClinicalTrials.gov Identifier: NCT01874353

Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenence Monotherapy in Platinum Sensitive relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy GINECO
SYMPTOM BENEFIT Does Palliative Chemotherapy Improve Symptoms in Women with Recurrent Ovarian Cancer?
TACO

ClinicalTrials.gov Identifier: NCT01561586

Tri-weekly Administration of Cisplatin in Locally Advanced Cervical Cancer KGOG
Tarceva Trial EORTC 55041

ClinicalTrials.gov Identifier: NCT00263822

A randomised, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer. EORTC-GCG